CPIM
ESPR

Columbia Partners Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Columbia Partners Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-21,220
Closed -$1.73M – 350
2015
Q2 		$1.73M Buy
+21,220
New +$2.08M 0.11% 199

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Columbia Partners Investment Management's ESPR Position: Q3 2015 in Review

Columbia Partners Investment Management sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 21,220 shares — an estimated $1.73M sold.

Columbia Partners Investment Management first reported a position in ESPR in Q2 2015 and held it in 1 quarter. The position peaked at $1.73M in Q2 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

  • Columbia Partners Investment Management reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Columbia Partners Investment Management sold 21,220 Esperion Therapeutics shares in Q3 2015, an estimated $1.73M.
  • Columbia Partners Investment Management first reported a position in Esperion Therapeutics in Q2 2015 and held it in 1 quarter.
  • Columbia Partners Investment Management's Esperion Therapeutics position peaked at $1.73M in Q2 2015.
  • 121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on Columbia Partners Investment Management's 13F filing for Q3 2015, filed 10 Nov 2015.